Table 4 Baroreflex sensitivity and resonance at baseline, on placebo, and on reb-oxy (n = 16).

From: Impact of reboxetine plus oxybutynin treatment for obstructive sleep apnea on cardiovascular autonomic modulation

 

Baseline

Placebo

Reb-Oxy

p-value

BRS ms/mmHg

 αLF supine

5.3 [3.8–8.6]

6.0 [4.2–8.8]

9.3 [7.8–10.8]

0.02

 αLF standing

2.6 [2.0–4.6]

3.1 [2.0–4.3]

3.7 [2.5–6.8]

0.03

 HLF supine

3.9 [2.8–6.6]

5.1 [3.5–6.8]

8.2 [5.8–10.5]

0.01

 HLF standing

2.0 [1.6–4.0]

2.2 [1.5–3.3]

3.1 [1.9–4.8]

0.07

 BRSSEQ supine

6.7 [4.2–7.6]

7.2 [3.3–9]

9.3 [8–12.6]

0.29

 BRSSEQ standing

3.9 [2.3–5.3]

3.4 [3.2–4.5]

3.9 [2.4–5]

0.08

Baroreflex resonance, mmHg2

 SBPLF supine

7.8 [3.9–14.2]

9.3 [4.7–11.7]

2.8 [2.1–3.8]

 < 0.01

 SBPLF standing

14.6 [11.2–20.4]

17.0 [10.9–21.4]

5.8 [4.2–9.8]

 < 0.01

 DBPLF supine

2.7 [1.9–5.3]

3.5 [1.8–5.8]

1.3 [1.1–2.0]

 < 0.01

 DBPLF standing

5.0 [3.8–9.2]

5.9 [4.1–9.4]

2.4 [1.7–3.4]

 < 0.01

  1. BRS: baroreflex sensitivity; SBP = systolic blood pressure; DBP = diastolic blood pressure; LF = low frequency; HLF = BRS estimation by transfer function technique in LF band and αLF = BRS estimation by spectral method in LF band (for further details, see methods). Data are expressed as percentage or median [interquartile].
  2. P values compare placebo versus reb-oxy.
  3. P-values are calculated by comparing the percent changes from baseline observed after placebo versus reb-oxy.